Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration

Ophthalmology

Volumn 120, Issue 5, 2013, Pages 1046-1056

  Busbee, Brandon G ^a   Ho, Allen C ^b   Brown, David M ^c   Heier, Jeffrey S ^d   Suñer, Ivan J ^e   Li, Zhengrong ^f   Rubio, Roman G ^f   Lai, Phillip ^f  

^a Tennessee Retina   (United States)

^b WILLS EYE HOSPITAL   (United States)

^c RETINA CONSULTANTS OF HOUSTON   (United States)

^d OPHTHALMIC CONSULTANTS OF BOSTON   (United States)

^e Retina Associates of Florida   (United States)

^f GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ADULT; AGED; ARTICLE; CENTRAL RETINAL THICKNESS; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; CONJUNCTIVAL HEMORRHAGE; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; IRIDOCYCLITIS; IRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA TEAR; TREATMENT DURATION; VISUAL ACUITY;

EID: 84877759606     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2012.10.014     Document Type: Article

References (21)

1. Eye Diseases Prevalence Research Group Prevalence of age-related macular degeneration in the United States Arch Ophthalmol 122 2004 564-2
2. T.Y. Wong, U. Chakravarthy, R. Klein The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis Ophthalmology 115 2008 116 126
3. N.M. Bressler Age-related macular degeneration is the leading cause of blindness JAMA 291 2004 1900 1901 (Pubitemid 38509505)
4. P.F. Lopez, B.D. Sippy, H.M. Lambert Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes Invest Ophthalmol Vis Sci 37 1996 855 868
5. M.G. Krzystolik, M.A. Afshari, A.P. Adamis Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment Arch Ophthalmol 120 2002 338 346 (Pubitemid 34250056)
6. D.M. Brown, P.K. Kaiser, M. Michels ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444 (Pubitemid 44511558)
7. D.M. Brown, M. Michels, P.K. Kaiser ANCHOR Study Group Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study Ophthalmology 116 2009 57 65
8. P.J. Rosenfeld, D.M. Brown, J.S. Heier MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431 (Pubitemid 44511557)
9. P.J. Rosenfeld, J.S. Heier, G. Hantsbarger, N. Shams Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration Ophthalmology 113 2006 623 632
10. D.M. Brown, E. Chen, A.F. Mariani, J.C. Major Superdose Anti-VEGF (SAVE) Trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular age-related macular degeneration-primary end point Ophthalmology 120 2013 349 354
11. C.D. Regillo, D.M. Brown, P. Abraham PIER Study Group Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1 Am J Ophthalmol 145 2008 239 248
12. P. Abraham, H. Yue, L. Wilson Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 2 Am J Ophthalmol 150 2010 315 324
13. CATT Research Group D.F. Martin, M.G. Maguire, G.S. Ying et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 2011 1897 1908
14. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group D.F. Martin, M.G. Maguire, S.L. Fine et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 2012 1388 1398
15. IVAN Study Investigators U. Chakravarthy, S.P. Harding, C.A. Rogers et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial Ophthalmology 119 2012 1399 1411
16. A.E. Fung, G.A. Lalwani, P.J. Rosenfeld An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration Am J Ophthalmol 143 2007 566 583
17. G.A. Lalwani, P.J. Rosenfeld, A.E. Fung A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study Am J Ophthalmol 148 2009 43 58
18. H.X. Chen, J.N. Cleck Adverse effects of anticancer agents that target the VEGF pathway Nat Rev Clin Oncol 6 2009 465 477
19. Ophthalmologic Drugs Advisory Committee VEGF Trap-Eye (aflibercept ophthalmic solution) Briefing Document June 17, 2011 Regeneron Pharmaceuticals, Inc. Tarrytown, NY 61 76 http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ DermatologicandOphthalmicDrugsAdvisoryCommittee/UCM259143.pdf Accessed March 27, 2012
20. D.S. Boyer, J.S. Heier, D.M. Brown A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration Ophthalmology 116 2009 1731 1739
21. Q.V. Hoang, L.S. Mendonca, K.E. Della Torre Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections Ophthalmology 119 2012 321 326